qPCR analyses of 14 tumor samples of patients without pCR after pembrolizumab revealed upregulation of genes associated with interferon-γ (IFN-γ) and resistance to immune therapy post-treatment compared to baseline [35]. This evidence concerns the gene IFNG and neoplasm.